KR100839322B1 - Ｂ형 간염 치료제 클레부딘의 개선된 제조방법 - Google Patents

Ｂ형 간염 치료제 클레부딘의 개선된 제조방법 Download PDF

Info

Publication number
KR100839322B1
KR100839322B1 KR1020060124497A KR20060124497A KR100839322B1 KR 100839322 B1 KR100839322 B1 KR 100839322B1 KR 1020060124497 A KR1020060124497 A KR 1020060124497A KR 20060124497 A KR20060124497 A KR 20060124497A KR 100839322 B1 KR100839322 B1 KR 100839322B1
Authority
KR
South Korea
Prior art keywords
clevudine
benzoyl
deoxy
alkali metal
thymine
Prior art date
Application number
KR1020060124497A
Other languages
English (en)
Korean (ko)
Other versions
KR20080052827A (ko
Inventor
우성주
박희광
송광호
한태희
구창휘
Original Assignee
부광약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 부광약품 주식회사 filed Critical 부광약품 주식회사
Priority to KR1020060124497A priority Critical patent/KR100839322B1/ko
Priority to PCT/KR2007/005441 priority patent/WO2008069451A1/fr
Priority to JO2007521A priority patent/JO2677B1/en
Publication of KR20080052827A publication Critical patent/KR20080052827A/ko
Application granted granted Critical
Publication of KR100839322B1 publication Critical patent/KR100839322B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020060124497A 2006-12-08 2006-12-08 Ｂ형 간염 치료제 클레부딘의 개선된 제조방법 KR100839322B1 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1020060124497A KR100839322B1 (ko) 2006-12-08 2006-12-08 Ｂ형 간염 치료제 클레부딘의 개선된 제조방법
PCT/KR2007/005441 WO2008069451A1 (fr) 2006-12-08 2007-10-31 Procédé amélioré de préparation de clévudine en tant qu'agent anti-vhb
JO2007521A JO2677B1 (en) 2006-12-08 2007-12-06 Improved process for the preparation of the clevudine compound as an anti-HBV agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060124497A KR100839322B1 (ko) 2006-12-08 2006-12-08 Ｂ형 간염 치료제 클레부딘의 개선된 제조방법

Publications (2)

Publication Number Publication Date
KR20080052827A KR20080052827A (ko) 2008-06-12
KR100839322B1 true KR100839322B1 (ko) 2008-06-17

Family

ID=39492283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020060124497A KR100839322B1 (ko) 2006-12-08 2006-12-08 Ｂ형 간염 치료제 클레부딘의 개선된 제조방법

Country Status (3)

Country Link
KR (1) KR100839322B1 (fr)
JO (1) JO2677B1 (fr)
WO (1) WO2008069451A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105943547B (zh) * 2016-05-23 2018-01-19 北京慧宝源生物技术股份有限公司 抗hbv的药物组合物及其应用
CN106831901A (zh) * 2016-12-14 2017-06-13 安徽省诚联医药科技有限公司 2‑脱氧‑2‑氟‑1,3,5‑三苯甲酰基‑α‑D‑阿拉伯呋喃糖的制备方法
CN109467583A (zh) * 2018-11-17 2019-03-15 扬州工业职业技术学院 一种克拉夫定的绿色合成工艺

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nuclear Medicine and BiologyVolume 30, Issue 3, April 2003, Pages 215-224*

Also Published As

Publication number Publication date
KR20080052827A (ko) 2008-06-12
JO2677B1 (en) 2013-03-03
WO2008069451A1 (fr) 2008-06-12

Similar Documents

Publication Publication Date Title
CN111205294A (zh) 一种瑞德西韦中间体的制备方法
AU2008327061B2 (en) Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein
JP2005139197A (ja) ５−メチルウリジンを用いる２’，３’−ジデヒドロ−３’−デオキシチミジン（ｄ４Ｔ）の製法
US9834561B2 (en) Process for preparing ibrutinib and its intermediates
KR100839322B1 (ko) Ｂ형 간염 치료제 클레부딘의 개선된 제조방법
DK2401253T3 (en) Method for producing etoricoxib
JP3677790B2 (ja) ヌクレオシド誘導体とその製造方法
CN111471070B (zh) 瑞德西韦的合成方法
KR20040031784A (ko) Ｌ-리바비린의 제조 방법
US7388094B2 (en) Processing for producing 2′-deoxy-2′-fluorouridine
JP6947354B2 (ja) リナグリプチンの製造法
JP4774676B2 (ja) ２’−デオキシ−２’−フルオロウリジンの製造方法
EP0350292A2 (fr) Procédé pour la préparation de 2'-déoxy-bêta-adénosine
KR101628946B1 (ko) 실로도신의 개선된 제조방법
KR101259648B1 (ko) 2′,2′-디플루오로뉴클레오시드 및 중간체의 새로운 제조방법
EP0495225A1 (fr) Procédé de préparation de nucléosides de 3'-fluoropyrimidine
CN112979736B (zh) 一种瑞德西韦的制备方法
US20090018325A1 (en) Process for preparing l-nucleic acid derivatives and intermediates thereof
US20030236397A1 (en) Process for preparing beta-L-2'deoxy-thymidine
KR100741310B1 (ko) 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
JPH06135988A (ja) ヌクレオシド誘導体
US7214791B2 (en) Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material
KR100528703B1 (ko) 5'-데옥시-5-플루오로우리딘의제조방법
AU2005275935A1 (en) Method for producing 2-(4-methyl-2-phenylpiperazine-1-yl)-3-cyanopiridine
JPH0597847A (ja) 核酸化合物の新規な製造方法

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130422

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20140403

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20160610

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20170412

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20180412

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 12